ArticleISRN dermatology2013
Clinical presentation, pathogenesis, diagnosis, and treatment of epidermolysis bullosa acquisita.
Article in ISRN dermatology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 99 citations in OpenAlex.
- Meta-analysis of the clinical and immunopathological characteristics and treatment outcomes in epidermolysis bullosa acquisita patients.Orphanet journal of rare diseases · 2018Pooled it
- Recombinant humanized type VII collagen for skin repair and regeneration: prospects for reconstructing the dermal-epidermal junction.Frontiers in medicine · 2026Review
- Current Knowledge on Nail Involvement in Autoimmune Bullous Disorders.Skin appendage disorders · 2024Review
- Clinical Features of Paediatric Inflammatory Epidermolysis Bullosa Acquisita: A Case Series Study.Acta dermato-venereologica · 2024Article
- Epidermolysis Bullosa Acquisita-Current and Emerging Treatments.Journal of clinical medicine · 2023Review
- Luteolin peracetate and gossypolone inhibit immune complex-mediated neutrophil activationFrontiers in immunology · 2023Article
- Case report: A case of epidermolysis bullosa acquisita with IgG and IgM anti-basement membrane zone antibodies relapsed after COVID-19 mRNA vaccination.Frontiers in medicine · 2023Article
- Case Report: Diagnostic and Therapeutic Challenges in Severe Mechanobullous Epidermolysis Bullosa Acquisita.Frontiers in immunology · 2022Article
- Strategies to Improve Outcomes of Bullous Pemphigoid: A Comprehensive Review of Clinical Presentations, Diagnosis, and Patients' Assessment.Clinical, cosmetic and investigational dermatology · 2022Review
- Bullous Autoimmune Dermatoses–Clinical Features, Diagnostic Evaluation, and Treatment Options.Deutsches Arzteblatt international · 2021Review
- Diagnostic Value and Practicability of Serration Pattern Analysis by Direct Immunofluorescence Microscopy in Pemphigoid Diseases.Acta dermato-venereologica · 2021Article
- Article
- Structural and biophysical characterization of the type VII collagen vWFA2 subdomain leads to identification of two binding sites.FEBS open bio · 2020Article
- Resolution in bullous pemphigoid.Seminars in immunopathology · 2019Review
- Consensus on the treatment of autoimmune bullous dermatoses: bullous pemphigoid, mucous membrane pemphigoid and epidermolysis bullosa acquisita - Brazilian Society of Dermatology.Anais brasileiros de dermatologia · 2019Article
- Proteases in Pemphigoid Diseases.Frontiers in immunology · 2019Review
- Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management.Clinical reviews in allergy & immunology · 2018Review
- Epidermolysis Bullosa Acquisita: The 2019 Update.Frontiers in medicine · 2018Review
- Diagnosis of Autoimmune Blistering Diseases.Frontiers in medicine · 2018Review
- Anti-Type VII Collagen Antibodies Are Identified in a Subpopulation of Bullous Pemphigoid Patients With Relapse.Frontiers in immunology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epidermolysis bullosa acquisita (EBA) is a chronic mucocutaneous autoimmune skin blistering disease. The pathogenic relevance of autoantibodies targeting type VII collagen (COL7) has been well-documented. Therefore, EBA is a prototypical autoimmune disease with a well-characterized pathogenic relevance of autoantibody binding to the target antigen. EBA is a rare disease with an incidence of 0.2 new cases per million and per year. The current treatment of EBA relies on general immunosuppressive therapy, which does not lead to remission in all cases. Therefore, there is a high, so far unmet medical need for the development of novel therapeutic options. During the last 10 years, several novel in vitro and in vivo models of EBA have been established. These models demonstrated a critical role of the genetic background, T cells, and cytokines for mediating the loss of tolerance towards COL7. Neutrophils, complement activation, Fc gamma receptor engagement, cytokines, several molecules involved in cell signaling, release of reactive oxygen species, and matrix metalloproteinases are crucial for autoantibody-induced tissue injury in EBA. Based on this growing understanding of the diseases' pathogenesis, several potential novel therapeutic targets have emerged. In this review, the clinical presentation, pathogenesis, diagnosis, and current treatment options for EBA are discussed in detail.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.